Single User License
INR 170050
Site License
INR 340100
Corporate User License
INR 510150

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


HIV / AIDS-Pipeline Review, H1 2015

HIV / AIDS-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

HIV / AIDS-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'HIV / AIDS-Pipeline Review, H1 2015', provides an overview of the HIV / AIDS's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV / AIDS, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV / AIDS and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of HIV / AIDS

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for HIV / AIDS and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the HIV / AIDS pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for HIV / AIDS

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 9

HIV / AIDS Overview 10

Therapeutics Development 11

HIV / AIDS-Therapeutics under Development by Companies 13

HIV / AIDS-Therapeutics under Investigation by Universities/Institutes 26

HIV / AIDS-Pipeline Products Glance 33

HIV / AIDS-Products under Development by Companies 37

HIV / AIDS-Products under Investigation by Universities/Institutes 55

HIV / AIDS-Companies Involved in Therapeutics Development 65

HIV / AIDS-Therapeutics Assessment 196

Drug Profiles 213

HIV / AIDS-Recent Pipeline Updates 703

HIV / AIDS-Dormant Projects 776

HIV / AIDS-Discontinued Products 812

HIV / AIDS-Product Development Milestones 819

Appendix 829

List of Tables

Number of Products under Development for HIV / AIDS, H1 2015 52

Number of Products under Development for HIV / AIDS-Comparative Analysis, H1 2015 53

Number of Products under Development by Companies, H1 2015 55

Number of Products under Development by Companies, H1 2015 (Contd..1) 56

Number of Products under Development by Companies, H1 2015 (Contd..2) 57

Number of Products under Development by Companies, H1 2015 (Contd..3) 58

Number of Products under Development by Companies, H1 2015 (Contd..4) 59

Number of Products under Development by Companies, H1 2015 (Contd..5) 60

Number of Products under Development by Companies, H1 2015 (Contd..6) 61

Number of Products under Development by Companies, H1 2015 (Contd..7) 62

Number of Products under Development by Companies, H1 2015 (Contd..8) 63

Number of Products under Development by Companies, H1 2015 (Contd..9) 64

Number of Products under Development by Companies, H1 2015 (Contd..10) 65

Number of Products under Development by Companies, H1 2015 (Contd..11) 66

Number of Products under Investigation by Universities/Institutes, H1 2015 67

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 69

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 70

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 71

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 72

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 73

Comparative Analysis by Late Stage Development, H1 2015 74

Comparative Analysis by Clinical Stage Development, H1 2015 75

Comparative Analysis by Early Stage Development, H1 2015 76

Comparative Analysis by Unknown Stage Development, H1 2015 77

Products under Development by Companies, H1 2015 78

Products under Development by Companies, H1 2015 (Contd..1) 79

Products under Development by Companies, H1 2015 (Contd..2) 80

Products under Development by Companies, H1 2015 (Contd..3) 81

Products under Development by Companies, H1 2015 (Contd..4) 82

Products under Development by Companies, H1 2015 (Contd..5) 83

Products under Development by Companies, H1 2015 (Contd..6) 84

Products under Development by Companies, H1 2015 (Contd..7) 85

Products under Development by Companies, H1 2015 (Contd..8) 86

Products under Development by Companies, H1 2015 (Contd..9) 87

Products under Development by Companies, H1 2015 (Contd..10) 88

Products under Development by Companies, H1 2015 (Contd..11) 89

Products under Development by Companies, H1 2015 (Contd..12) 90

Products under Development by Companies, H1 2015 (Contd..13) 91

Products under Development by Companies, H1 2015 (Contd..14) 92

Products under Development by Companies, H1 2015 (Contd..15) 93

Products under Development by Companies, H1 2015 (Contd..16) 94

Products under Development by Companies, H1 2015 (Contd..17) 95

Products under Investigation by Universities/Institutes, H1 2015 96

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 97

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 98

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 99

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 100

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 101

Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 102

Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 103

Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 104

Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 105

HIV / AIDS-Pipeline by Abivax S.A., H1 2015 106

HIV / AIDS-Pipeline by Adaptimmune Limited, H1 2015 107

HIV / AIDS-Pipeline by AiCuris GmbH & Co. KG, H1 2015 108

HIV / AIDS-Pipeline by Akshaya Bio Inc., H1 2015 109

HIV / AIDS-Pipeline by AlphaVax, Inc., H1 2015 110

HIV / AIDS-Pipeline by Altor BioScience Corporation, H1 2015 111

HIV / AIDS-Pipeline by AltraVax Inc., H1 2015 112

HIV / AIDS-Pipeline by Amarna Therapeutics B.V., H1 2015 113

HIV / AIDS-Pipeline by American Gene Technologies International Inc., H1 2015 114

HIV / AIDS-Pipeline by Amplyx Pharmaceuticals, Inc., H1 2015 115

HIV / AIDS-Pipeline by Antigen Express, Inc., H1 2015 116

HIV / AIDS-Pipeline by Aphios Corporation, H1 2015 117

HIV / AIDS-Pipeline by Argos Therapeutics, Inc., H1 2015 118

HIV / AIDS-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 119

HIV / AIDS-Pipeline by Avexa Limited, H1 2015 120

HIV / AIDS-Pipeline by BCI Pharma, H1 2015 121

HIV / AIDS-Pipeline by BioClonetics Immunotherapeutics, Inc., H1 2015 122

HIV / AIDS-Pipeline by Bionor Pharma ASA, H1 2015 123

HIV / AIDS-Pipeline by Biosantech SA, H1 2015 124

HIV / AIDS-Pipeline by Biotron Limited, H1 2015 125

HIV / AIDS-Pipeline by Boehringer Ingelheim GmbH, H1 2015 126

HIV / AIDS-Pipeline by Bristol-Myers Squibb Company, H1 2015 127

HIV / AIDS-Pipeline by C4X Discovery Limited, H1 2015 128

HIV / AIDS-Pipeline by Calimmune, Inc., H1 2015 129

HIV / AIDS-Pipeline by Celldex Therapeutics, Inc., H1 2015 130

HIV / AIDS-Pipeline by CompleGen, Inc., H1 2015 131

HIV / AIDS-Pipeline by Critical Outcome Technologies Inc., H1 2015 132

HIV / AIDS-Pipeline by CureVac GmbH, H1 2015 133

HIV / AIDS-Pipeline by CytoDyn Inc., H1 2015 134

HIV / AIDS-Pipeline by DNAVEC Corporation, H1 2015 135

HIV / AIDS-Pipeline by Enzo Biochem, Inc., H1 2015 136

HIV / AIDS-Pipeline by EpiVax, Inc., H1 2015 137

HIV / AIDS-Pipeline by Etubics Corporation, H1 2015 138

HIV / AIDS-Pipeline by Farmsintez, H1 2015 139

HIV / AIDS-Pipeline by FIT Biotech Oy, H1 2015 140

HIV / AIDS-Pipeline by Fountain Biopharma Inc., H1 2015 141

HIV / AIDS-Pipeline by Frontier Biotechnologies Co., Ltd, H1 2015 142

HIV / AIDS-Pipeline by GeneCure LLC, H1 2015 143

HIV / AIDS-Pipeline by Genetic Immunity, Inc, H1 2015 144

HIV / AIDS-Pipeline by Genticel S.A., H1 2015 145

HIV / AIDS-Pipeline by GeoVax Labs, Inc., H1 2015 146

HIV / AIDS-Pipeline by Gilead Sciences, Inc., H1 2015 147

HIV / AIDS-Pipeline by GlaxoSmithKline Plc, H1 2015 148

HIV / AIDS-Pipeline by Globeimmune, Inc., H1 2015 149

HIV / AIDS-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 150

HIV / AIDS-Pipeline by Heat Biologics, Inc., H1 2015 151

HIV / AIDS-Pipeline by Heptares Therapeutics Limited, H1 2015 152

HIV / AIDS-Pipeline by Hetero Drugs Limited, H1 2015 153

HIV / AIDS-Pipeline by Humabs BioMed SA, H1 2015 154

HIV / AIDS-Pipeline by iCo Therapeutics Inc., H1 2015 155

HIV / AIDS-Pipeline by Immune Response BioPharma, Inc., H1 2015 156

HIV / AIDS-Pipeline by Immunocore Limited, H1 2015 157

HIV / AIDS-Pipeline by ImmunoGenetix Therapeutics, Inc., H1 2015 158

HIV / AIDS-Pipeline by Immunomic Therapeutics, Inc., H1 2015 159

HIV / AIDS-Pipeline by Immunotech Laboratories, Inc., H1 2015 160

HIV / AIDS-Pipeline by Immuron Limited, H1 2015 161

HIV / AIDS-Pipeline by ImQuest Life Sciences, H1 2015 162

HIV / AIDS-Pipeline by InnaVirVax SA, H1 2015 163

HIV / AIDS-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 164

HIV / AIDS-Pipeline by Japan Tobacco Inc., H1 2015 165

HIV / AIDS-Pipeline by Johnson & Johnson, H1 2015 166

HIV / AIDS-Pipeline by Kineta, Inc., H1 2015 167

HIV / AIDS-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 168

HIV / AIDS-Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015 169

HIV / AIDS-Pipeline by Longevity Biotech, Inc, H1 2015 170

HIV / AIDS-Pipeline by Medestea Research & Production S.p.A., H1 2015 171

HIV / AIDS-Pipeline by Medivir AB, H1 2015 172

HIV / AIDS-Pipeline by Merck & Co., Inc., H1 2015 173

HIV / AIDS-Pipeline by Mologen AG, H1 2015 174

HIV / AIDS-Pipeline by Mymetics Corporation, H1 2015 175

HIV / AIDS-Pipeline by Myrexis, Inc., H1 2015 176

HIV / AIDS-Pipeline by NanoBio Corporation, H1 2015 177

HIV / AIDS-Pipeline by NanoViricides, Inc., H1 2015 178

HIV / AIDS-Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 179

HIV / AIDS-Pipeline by NeED Pharma s.r.l., H1 2015 180

HIV / AIDS-Pipeline by Nektar Therapeutics, H1 2015 181

HIV / AIDS-Pipeline by Novartis AG, H1 2015 182

HIV / AIDS-Pipeline by Omeros Corporation, H1 2015 183

HIV / AIDS-Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 184

HIV / AIDS-Pipeline by Oncolys BioPharma Inc., H1 2015 185

HIV / AIDS-Pipeline by OncoNOx ApS, H1 2015 186

HIV / AIDS-Pipeline by Oncovir, Inc., H1 2015 187

HIV / AIDS-Pipeline by Orbis Biosciences, Inc., H1 2015 188

HIV / AIDS-Pipeline by Osel Inc., H1 2015 189

HIV / AIDS-Pipeline by OyaGen Inc., H1 2015 190

HIV / AIDS-Pipeline by PaxVax, H1 2015 191

HIV / AIDS-Pipeline by Pepscan Therapeutics, H1 2015 192

HIV / AIDS-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 193

HIV / AIDS-Pipeline by Pfizer Inc., H1 2015 194

HIV / AIDS-Pipeline by Pharis Biotec GmbH, H1 2015 195

HIV / AIDS-Pipeline by Phoenix Biotechnology, Inc., H1 2015 196

HIV / AIDS-Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2015 197

HIV / AIDS-Pipeline by Presidio Pharmaceuticals, Inc., H1 2015 198

HIV / AIDS-Pipeline by Profectus BioSciences, Inc., H1 2015 199

HIV / AIDS-Pipeline by Quantum Pharmaceuticals, H1 2015 200

HIV / AIDS-Pipeline by RAPID Pharmaceuticals AG, H1 2015 201

HIV / AIDS-Pipeline by Recombio S.L, H1 2015 202

HIV / AIDS-Pipeline by Rodos BioTarget GmbH, H1 2015 203

HIV / AIDS-Pipeline by Rottapharm SpA, H1 2015 204

HIV / AIDS-Pipeline by Sangamo BioSciences, Inc., H1 2015 205

HIV / AIDS-Pipeline by Sanofi, H1 2015 206

HIV / AIDS-Pipeline by Sanofi Pasteur SA, H1 2015 207

HIV / AIDS-Pipeline by SEEK Group, H1 2015 208

HIV / AIDS-Pipeline by Sequoia Pharmaceuticals, Inc., H1 2015 209

HIV / AIDS-Pipeline by Serometrix, LLC, H1 2015 210

HIV / AIDS-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 211

HIV / AIDS-Pipeline by SKAU Vaccines ApS, H1 2015 212

HIV / AIDS-Pipeline by Spider Biotech, H1 2015 213

HIV / AIDS-Pipeline by Starpharma Holdings Limited, H1 2015 214

HIV / AIDS-Pipeline by Sumagen Co., Ltd., H1 2015 215

HIV / AIDS-Pipeline by Taiga Biotechnologies, Inc., H1 2015 216

HIV / AIDS-Pipeline by TaiMed Biologics Inc., H1 2015 217

HIV / AIDS-Pipeline by Takara Bio Inc., H1 2015 218

HIV / AIDS-Pipeline by TAmiRNA GmbH, H1 2015 219

HIV / AIDS-Pipeline by TechnoVax, Inc., H1 2015 220

HIV / AIDS-Pipeline by TetraLogic Pharmaceuticals, H1 2015 221

HIV / AIDS-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 222

HIV / AIDS-Pipeline by Theraclone Sciences, Inc., H1 2015 223

HIV / AIDS-Pipeline by Theravectys S.A., H1 2015 224

HIV / AIDS-Pipeline by Tobira Therapeutics, Inc., H1 2015 225

HIV / AIDS-Pipeline by Transgene Biotek Limited, H1 2015 226

HIV / AIDS-Pipeline by TVAX Biomedical, Inc., H1 2015 227

HIV / AIDS-Pipeline by United Biomedical, Inc., H1 2015 228

HIV / AIDS-Pipeline by United Therapeutics Corporation, H1 2015 229

HIV / AIDS-Pipeline by Vaccibody AS, H1 2015 230

HIV / AIDS-Pipeline by VG Life Sciences, Inc., H1 2015 231

HIV / AIDS-Pipeline by Vichem Chemie Research Ltd., H1 2015 232

HIV / AIDS-Pipeline by ViiV Healthcare Limited, H1 2015 233

HIV / AIDS-Pipeline by Viriom Ltd., H1 2015 234

HIV / AIDS-Pipeline by ViroLogik GmbH, H1 2015 235

HIV / AIDS-Pipeline by ViroXis Corporation, H1 2015 236

Assessment by Monotherapy Products, H1 2015 237

Assessment by Combination Products, H1 2015 238

Number of Products by Stage and Target, H1 2015 240

Number of Products by Stage and Mechanism of Action, H1 2015 245

Number of Products by Stage and Route of Administration, H1 2015 251

Number of Products by Stage and Molecule Type, H1 2015 253

HIV / AIDS Therapeutics-Recent Pipeline Updates, H1 2015 744

HIV / AIDS-Dormant Projects, H1 2015 817

HIV / AIDS-Dormant Projects (Contd..1), H1 2015 818

HIV / AIDS-Dormant Projects (Contd..2), H1 2015 819

HIV / AIDS-Dormant Projects (Contd..3), H1 2015 820

HIV / AIDS-Dormant Projects (Contd..4), H1 2015 821

HIV / AIDS-Dormant Projects (Contd..5), H1 2015 822

HIV / AIDS-Dormant Projects (Contd..6), H1 2015 823

HIV / AIDS-Dormant Projects (Contd..7), H1 2015 824

HIV / AIDS-Dormant Projects (Contd..8), H1 2015 825

HIV / AIDS-Dormant Projects (Contd..9), H1 2015 826

HIV / AIDS-Dormant Projects (Contd..10), H1 2015 827

HIV / AIDS-Dormant Projects (Contd..11), H1 2015 828

HIV / AIDS-Dormant Projects (Contd..12), H1 2015 829

HIV / AIDS-Dormant Projects (Contd..13), H1 2015 830

HIV / AIDS-Dormant Projects (Contd..14), H1 2015 831

HIV / AIDS-Dormant Projects (Contd..15), H1 2015 832

HIV / AIDS-Dormant Projects (Contd..16), H1 2015 833

HIV / AIDS-Dormant Projects (Contd..17), H1 2015 834

HIV / AIDS-Dormant Projects (Contd..18), H1 2015 835

HIV / AIDS-Dormant Projects (Contd..19), H1 2015 836

HIV / AIDS-Dormant Projects (Contd..20), H1 2015 837

HIV / AIDS-Dormant Projects (Contd..21), H1 2015 838

HIV / AIDS-Dormant Projects (Contd..22), H1 2015 839

HIV / AIDS-Dormant Projects (Contd..23), H1 2015 840

HIV / AIDS-Dormant Projects (Contd..24), H1 2015 841

HIV / AIDS-Dormant Projects (Contd..25), H1 2015 842

HIV / AIDS-Dormant Projects (Contd..26), H1 2015 843

HIV / AIDS-Dormant Projects (Contd..27), H1 2015 844

HIV / AIDS-Dormant Projects (Contd..28), H1 2015 845

HIV / AIDS-Dormant Projects (Contd..29), H1 2015 846

HIV / AIDS-Dormant Projects (Contd..30), H1 2015 847

HIV / AIDS-Dormant Projects (Contd..31), H1 2015 848

HIV / AIDS-Dormant Projects (Contd..32), H1 2015 849

HIV / AIDS-Dormant Projects (Contd..33), H1 2015 850

HIV / AIDS-Dormant Projects (Contd..34), H1 2015 851

HIV / AIDS-Dormant Projects (Contd..35), H1 2015 852

HIV / AIDS-Discontinued Products, H1 2015 853

HIV / AIDS-Discontinued Products (Contd..1), H1 2015 854

HIV / AIDS-Discontinued Products (Contd..2), H1 2015 855

HIV / AIDS-Discontinued Products (Contd..3), H1 2015 856

HIV / AIDS-Discontinued Products (Contd..4), H1 2015 857

HIV / AIDS-Discontinued Products (Contd..5), H1 2015 858

HIV / AIDS-Discontinued Products (Contd..6), H1 2015 859

List of Figures

Number of Products under Development for HIV / AIDS, H1 2015 52

Number of Products under Development for HIV / AIDS-Comparative Analysis, H1 2015 53

Number of Products under Development by Companies, H1 2015 54

Number of Products under Investigation by Universities/Institutes, H1 2015 67

Comparative Analysis by Late Stage Development, H1 2015 74

Comparative Analysis by Clinical Stage Development, H1 2015 75

Comparative Analysis by Early Stage Products, H1 2015 76

Assessment by Monotherapy Products, H1 2015 237

Assessment by Combination Products, H1 2015 238

Number of Products by Top 10 Targets, H1 2015 239

Number of Products by Stage and Top 10 Targets, H1 2015 239

Number of Products by Top 10 Mechanism of Actions, H1 2015 244

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 244

Number of Products by Top 10 Routes of Administration, H1 2015 250

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 250

Number of Products by Top 10 Molecule Types, H1 2015 252

Number of Products by Stage and Top 10 Molecule Types, H1 2015 252

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax S.A.

Adaptimmune Limited

AiCuris GmbH & Co. KG

Akshaya Bio Inc.

AlphaVax, Inc.

Altor BioScience Corporation

AltraVax Inc.

Amarna Therapeutics B.V.

American Gene Technologies International Inc.

Amplyx Pharmaceuticals, Inc.

Antigen Express, Inc.

Aphios Corporation

Argos Therapeutics, Inc.

Astex Pharmaceuticals, Inc.

Avexa Limited

BCI Pharma

BioClonetics Immunotherapeutics, Inc.

Bionor Pharma ASA

Biosantech SA

Biotron Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

C4X Discovery Limited

Calimmune, Inc.

Celldex Therapeutics, Inc.

CompleGen, Inc.

Critical Outcome Technologies Inc.

CureVac GmbH

CytoDyn Inc.

DNAVEC Corporation

Enzo Biochem, Inc.

EpiVax, Inc.

Etubics Corporation

Farmsintez

FIT Biotech Oy

Fountain Biopharma Inc.

Frontier Biotechnologies Co., Ltd

GeneCure LLC

Genetic Immunity, Inc

Genticel S.A.

GeoVax Labs, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Globeimmune, Inc.

Hadasit Medical Research Services & Development Ltd

Heat Biologics, Inc.

Heptares Therapeutics Limited

Hetero Drugs Limited

Humabs BioMed SA

iCo Therapeutics Inc.

Immune Response BioPharma, Inc.

Immunocore Limited

ImmunoGenetix Therapeutics, Inc.

Immunomic Therapeutics, Inc.

Immunotech Laboratories, Inc.

Immuron Limited

ImQuest Life Sciences

InnaVirVax SA

Inovio Pharmaceuticals, Inc.

Japan Tobacco Inc.

Johnson & Johnson

Kineta, Inc.

Laboratorios Del Dr. Esteve S.A.

Laila Pharmaceuticals Pvt. Ltd.

Longevity Biotech, Inc

Medestea Research & Production S.p.A.

Medivir AB

Merck & Co., Inc.

Mologen AG

Mymetics Corporation

Myrexis, Inc.

NanoBio Corporation

NanoViricides, Inc.

Navigen Pharmaceuticals, Inc.

NeED Pharma s.r.l.

Nektar Therapeutics

Novartis AG

Omeros Corporation

Omni Bio Pharmaceutical Inc.

Oncolys BioPharma Inc.

OncoNOx ApS

Oncovir, Inc.

Orbis Biosciences, Inc.

Osel Inc.

OyaGen Inc.

PaxVax

Pepscan Therapeutics

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharis Biotec GmbH

Phoenix Biotechnology, Inc.

Polymun Scientific Immunbiologische Forschung GmbH

Presidio Pharmaceuticals, Inc.

Profectus BioSciences, Inc.

Quantum Pharmaceuticals

RAPID Pharmaceuticals AG

Recombio S.L

Rodos BioTarget GmbH

Rottapharm SpA

Sangamo BioSciences, Inc.

Sanofi

Sanofi Pasteur SA

SEEK Group

Sequoia Pharmaceuticals, Inc.

Serometrix, LLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

SKAU Vaccines ApS

Spider Biotech

Starpharma Holdings Limited

Sumagen Co., Ltd.

Taiga Biotechnologies, Inc.

TaiMed Biologics Inc.

Takara Bio Inc.

TAmiRNA GmbH

TechnoVax, Inc.

TetraLogic Pharmaceuticals

Teva Pharmaceutical Industries Limited

Theraclone Sciences, Inc.

Theravectys S.A.

Tobira Therapeutics, Inc.

Transgene Biotek Limited

TVAX Biomedical, Inc.

United Biomedical, Inc.

United Therapeutics Corporation

Vaccibody AS

VG Life Sciences, Inc.

Vichem Chemie Research Ltd.

ViiV Healthcare Limited

Viriom Ltd.

ViroLogik GmbH

ViroXis Corporation

HIV / AIDS Therapeutic Products under Development, Key Players in HIV / AIDS Therapeutics, HIV / AIDS Pipeline Overview, HIV / AIDS Pipeline, HIV / AIDS Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com